BioSpace News Archive

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced an update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is developing with its partner, Moffitt Cancer Center.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today updated data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized research-driven cannabis extraction, distillation and purification, today announced that the Australian Therapeutic Goods Administration (the “TGA”) has notified the Company that its Canadian manufacturing facility meets the requirements for Good Manufacturing Practice for Medicinal Products (“GMP”)

Bristol-Myers Squibb Company (NYSE:BMY) announced today that John Elicker, Executive Vice President, Corporate Affairs and Investor Relations, will retire from the company March 31, 2020.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) announces a proposed shares-for-debt transaction in which the Company would issue 192,907 common shares, at a price of CAD $0.41 per share, to an arm’s length third party creditor of the Company in connection with the settlement of an aggregate of USD $60,000 of debt.

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) in adults with chronic heart failure with reduced and preserved ejection fraction, respectively.

Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that the merger with Privateer Holdings, Inc. (“Privateer”), closed on December 12, 2019.

Data presented at 2019 San Antonio Breast Cancer Symposium demonstrates the value of blood-based comprehensive genomic profiling in metastatic breast cancer

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced results from a pivotal Phase III clinical trial showed oral paclitaxel and encequidar had superior response and survival with much lower incidence and severity of neuropathy compared to IV paclitaxel in the treatment of metastatic breast cancer

Lumeca Health, one of Canada’s leading virtual healthcare platforms, is proud to announce its recent acquisition of one of Saskatchewan’s most successful tech startup development team.